Find an expert

I am a medicinal chemist and postdoctoral research fellow at the University of Queensland, Australia, where I obtained my BSc (Hons) with a major in organic chemistry in 2011. Following this, I worked at the Institute for Future Environments and later the Centre for Tropical Crops and Biocommodities at QUT, where I gained experience in analytical chemistry, as well as molecular biology and genetics. In 2015, I returned to UQ to begin my PhD in the design and synthesis of novel antifungals targeting invasive infection under the supervision of Prof. Craig Williams and Prof. Luke Guddat, which I completed in 2019. Since this time I have worked at the School of Chemistry and Molecular Biosciences as a Postdoctoral Research Fellow under the supervision of Prof. Craig Williams, Prof. Avril Robertson, and now Prof. James De Voss. Broadly, my research interests lie in the pursuit of drug design and development campaigns addressing difficult or under-researched clinical concerns, and in particular, the use of novel bioisosteric approaches to improve drugability and drug efficacy.

More recently, I have developed an interest in Australian mushroom species. Very little recorded knowledge on our endemic mushrooms species exists. My research in this space seeks to characterise the genetic and molecular features of Australian wood rot mushrooms, which are critical players in maintaining and restoring the health of our unique forests ecosystems. With this information we aim to better understand our fungal biodiversity and the ecological roles they play, and to explore their potential as a platform for the identification of new drug molecules.

Dr Sandra Brosda is a Research Fellow within the Surgical Oncology group led by Professor Andrew Barbour.

Dr Brosda was awarded a PhD in bioinformatics and cancer genetics from the University of Queensland in November 2020. Her research focused on biomarker discovery and intra-tumour heterogeneity and tumour evolution in oesophageal adenocarcinoma (OAC). In 2021, Dr Brosda was awarded a Cure Cancer Australia PdCCRS grant and an MSH project grant to further investigate tumour evolution to improve precision medicine in OAC.

She has been involved in research projects covering genetics, epigenetics, spatial transcriptomics, radiomics, ctDNA and quality of life assessments in the context of cancer. Overall, her research applies bioinformatics tools and approaches to cancer genomics to improve precision medicine and health outcomes for patients with melanoma, oesophago-gastric cancer and pancreatic cancer.

A/Prof. Seth Cheetham is an ARC Discovery Early Career Award Fellow and Group Leader at the Australian Institute for Bioengineering and Nanotechnology. He is also the Deputy Director of the BASE facility, Australia's leading mRNA manufacturing hub. He completed his PhD at the University of Cambridge, supported by the Herchel Smith Research Studentship. Seth is a molecular biologist and geneticist with a focus on mRNA drugs, synthetic biology and epigenetics. He has authored 25 publications, in some of the most influential molecular biology journals including Science, Molecular Cell, Nature Reviews Genetics , Genome Biology and Nature Structural and Molecular Biology. His work has attracted > $15M including back-to-back NHMRC and ARC Fellowships. In 2021 Seth was awarded the Genetics Society of Australasia Alan Wilton ECR awarded for his research in the field of RNA and epigenetics.

David is a Consultant Paediatrician, Metabolic Physician, Clinical Geneticist and clinician researcher. His area of expertise is the diagnosis and management of children with rare diseases. David is involved in multiple ongoing research projects aimed at novel disease discovery, improved diagnostic testing and treatments for children with inherited genetic disorders. He is director of a national clinic for Ataxia Telangiectasia brashat.org.au and has recently been awarded a $2.5 million NHMRC research grant for a phase 2/3 trial for treatment of this disorder.

Evolutionary and ecological genomics of marine invertebrate animals.

My lab's research is driven by a fascination with genomes that carry within them endless, brilliant solutions forged by evolution over millions of years in response to a constantly changing ocean. We tap into this to learn how the genomes of coral reef invertebrates and their bacterial symbionts interact with each other, and with the environment, throughout their life cycle. We study these gene-environment interactions in evolutionary and ecological contexts, using genomic, molecular and cellular approaches combined with behavioural ecology in natural populations.

We work often with embryonic and larval life history stages of indirect developers, as these stages are crucial to the maintenance and evolution of marine populations. Our current focus is around larval settlement and metamorphosis in the holobiont of the coral reef demosponge Amphimedon queenslandica. In recent years, our work has extended to functional genomic approaches to identify noval ways to control the coral reef pest, the Crown-of-Thorns starfish.

When not immersed in the molecular or computer lab, we are lucky enough to be immersed in the ocean, often in beautiful places!

Plant viruses and horticultural crop improvement

Dr Dietzgen is internationally recognised for his work on plant virus characterisation, detection and engineered resistance. Before joining UQ, Dr Dietzgen was a Science Leader in Agri-Science in the Queensland Department of Employment, Economic Development and Innovation. He previously held research positions at the University of Adelaide, University of California, Cornell University and University of Kentucky. Dr Dietzgen’s research interests are in molecular virus-plant-insect interactions, virus biodiversity and evolution, and disease resistance mechanisms. His focus is on the biology of RNA viruses in the family Rhabdoviridae and the molecular protein interactions of plant-adapted rhabdoviruses and tospoviruses. He has published extensively on plant virus characterisation and genetic variability, RNAi- mediated virus resistance and diagnostic technologies with 20 review articles and book chapters and over 65 peer-reviewed publications.

Genetics of mental health (new research)

We are using the genetic model organism, C. elegans, do investigate the genetic basis of both normal and disordered behaviour. Our current interests are identifying the genes responsible for anxiety and depression as well as the genes for eating disoders and addiction. Using C. elegans as a model organism will also allow us to study gene function as it relates to behaviour.

Molecular mechanisms of phosphine resistance (other research)

Genetic mapping of oxidative stress resistance genes. The fumigant phosphine disrupts oxidative metabolism, resulting in the production of reactive oxygen intermediates. This causes the premature ageing and death of targeted pests. Insect pests of stored grain in Australia now exhibit resistance to phosphine at levels more than 200 times the normal lethal dose.

We have genetically mappedf and identified the genes responsible for phosphine resistance in tall major insect pests of stored grain. We are using a systems biology approach in the model organism C. elegans to understand the molecular basis of phosphine action. Our genetic studies have recently shown that resistance to phosphine is associated with an extension of lifespan

Dr. Forutan is an internationally recognized Researcher. Her research area includes understanding the bovine genome and epigenome, discovering causative mutation underlying economic important traits such as fertility, understanding the way genes turn on and off, investigating different methodologies to improve the accuracy of genomic prediction, and optimizing methods for predicting genetic diversity and inbreeding. Her future research career vision is to make a significant contribution to creating new knowledge in the field of quantitative genetics that can help to improve efficiency and resilience in Livestock.

After completing his BSc and MSc (Hons) at the University of Canterbury (NZ), Dylan worked for five years as a Research Scientist at Antisoma Research Limited (London, UK), developing antibody-enzyme fusion proteins for cancer therapy. He returned to New Zealand to carry out his PhD research into antidepressant pharmacogenomics at the University of Otago. Afterwards, he continued working at the University of Otago as a Research Fellow, studying the biological function of genes involved with inflammatory bowel disease. Dylan moved to the United States in 2009 to perform postdoctoral training, researching the functional genetics of the VEGF-pathway and its relationship with cancer at the University of Chicago and, subsequently, the University of North Carolina, Chapel Hill.

In 2013, Dylan began working at QIMR Berghofer and has undertaken the functional follow-up of large-scale genetic studies of breast, endometrial and ovarian cancer to identify the likely causal variants and genes that mediate associations with cancer risk and survival. He has been awarded both internal and NHMRC grant funding to support these studies. Since 2019, Dylan has held an Honorary Associate Professorship at UQ

As of early 2021, Dylan has authored one conference report, two editorials, two book chapters, six reviews and 31 original research articles. He is first or last author on 20 of these publications and 27 of his publications have been cited at least 10 times. According to CiteScore, since 2010, 53% of his articles have been published in journals ranked in the top 10% and 19% of hispublications are in the 10% most cited publications worldwide.

(she/her)

Dr. Laura Grogan is a qualified veterinarian, Senior Lecturer in Wildlife Science and Leader of the Biodiversity Health Research Team (https://www.biodiversity-health.org/) - a collaborative multiple-university research group focused on finding sustainable solutions for the most challenging threatening processes currently affecting biodiversity.

Dr. Grogan has a background in research on wildlife diseases, ecology and conservation. She's particularly interested in investigating the dynamics, relative importance, and impacts of infectious diseases among other threats affecting wildlife across both individual and population scales, to improve conservation management.

While she works across taxa and methodological approaches, her main study system currently involves the devastating amphibian fungal skin disease, chytridiomycosis, where at the individual scale she focuses on the pathogenesis and amphibian immune response to the disease, untangling the roles of resistance and tolerance in defense against infection. At the population and landscape scale she explores mechanisms underlying persistence in the face of endemic infection, focused on the endangered Fleay's barred frog. She also studies population and infection dynamics of chlamydiosis in koala using a mathematical modelling approach, exploring the relative benefits of different management approaches. In addition to working on amphibian and koala diseases, Laura is a keen birdwatcher, wildlife photographer and artist. She supervises projects across wildlife-related fields (predominantly vertebrates).

You can find out more about her research team here: www.biodiversity-health.org.

Dr. Grogan has been awarded around $1.3 million in research funding since 2018. In late 2019 she was awarded an Australian Research Council Discovery Early Career Researcher Award (DECRA; DE200100490), worth $426,742. This project, titled "Understanding infection tolerance to improve management of wildlife disease", commenced in late 2020. Dr. Grogan was identified as one of the four top-ranked science DECRA awardees by the Australian Academy of Science’s 2020 J G Russell Award, and was also recipient of the highest award of the Wildlife Disease Association Australasia Section with their 2019 Barry L Munday Recognition Award.

PhD and Honours projects are now available in the following areas (plus many more areas - please get in touch if you have an idea):

• Can frogs be ‘vaccinated’ by antifungal treatment of active infections to develop protective immunity to the devastating chytrid fungus? (Principal Supervisor)
• Establishing the conservation status of south-east Queensland’s amphibians - occupancy surveys and species distribution models (Principal Supervisor)
• Tadpoles as a reservoir of the lethal frog chytrid fungal disease – measuring sublethal effects on growth, time to metamorphosis and ability to forage (mouthpart loss) (Principal Supervisor)
• Impacts of chytrid fungus on the survival of juvenile endangered Fleay’s barred frogs, Mixophyes fleayi, and importance for population recruitment (Principal Supervisor)
• Measuring the infection resistance versus tolerance of barred frogs to the devastating chytrid fungal disease to improve management outcomes (Principal Supervisor)
• Mapping the impacts of fire-fighting chemicals on endangered frog habitats (Co-Supervisor)
• Bowra birds: what do long-term monitoring data reveal about bird communities in the semi-arid region? (Co-Supervisor)
• Impacts of fire-fighting chemicals on endangered frogs: Implications for conservation and management (Co-Supervisor)

Dr. Wenyi Gu’s early education was conducted in China which include his undergraduate and master’s degrees in veterinary medicine. In 1996, he migrated to Australia and pursued his PhD study in biochemistry & molecular biology at the Australian National University (ANU). After a short period of work at John Curtin Medical School ANU as a junior scientist, he moved to Brisbane in 2001 for his post-doc at the University of Queensland and currently a post-doctoral research fellow at AIBN. He held a Peter Doherty Fellowship (2006-2009) and was further supported by NHMRC to spend 7 months at Harvard University as a visiting fellow in 2008. Since his post-doctoral research he has been working in the area of using RNAi to treat viral diseases and cancers. He also has a strong background in immunology and vaccine development.

Dr. Guoquan Liu has more than ten years experience in sorghum tissue culture and genetic transformation. He developed a highly efficient sorghum particle transformation system in 2012. Since then, hundreds of transgenic plants have been regenerated from tens of constructs that are invoved in plant disease resistant genes (e.g. Lr34), report gene (gfp), specific-promoters (e.g. alpha- beta- kafirin, A2, LSG), G proteins etc.. He has trained many students how to transform sorghum including honor students, master students, and PhD students.

He has focused on improving sorghum grain yield and grain quality through biotechnologies including genetic transformation, genome-editing, synthetic biology, and plant apomixis.

Dr Quan Nguyen is a Group Leader at the Institute for Molecular Bioscience (IMB), The University of Queensland. He is leading the Genomics and Machine Learning (GML) lab to study neuroinflammation and cancer-immune cells at single-cell resolution and within spatial morphological tissue context. His research interest is about revealing gene and cell regulators that determine the states of the complex cancer and neuronal ecosystems. Particularly, he is interested in quantifying cellular diversity and the dynamics of cell-cell interactions within the tissues to find ways to improve cancer diagnosis or cell-type specific treatments or the immunoinflammation responses that cause neuronal disease.

Using machine learning and genomic approaches, his group are integrating single-cell spatiotemporal sequencing data with tissue imaging data to find causal links between cellular genotypes, tissue microenvironment, and disease phenotypes. GML lab is also developing experimental technologies that enable large-scale profiling of spatial gene and protein expression (spatial omics) in a range of cancer tissues (focusing on brain and skin cancer) and in mouse brain and spinal cord.

Dr Quan Nguyen completed a PhD in Bioengineering at the University of Queensland in 2013, postdoctoral training in Bioinformatics at RIKEN institute in Japan in 2015, a CSIRO Office of Chief Executive (OCE) Research Fellowship in 2016, an IMB Fellow in 2018, an Australian Research Council DECRA fellowship (2019-2021), and is currently a National Health and Medical Research Council leadership fellow (EL2). He has published in top-tier journals, including Cell, Cell Stem Cell, Nature Methods, Nature Protocols, Nature Communications, Genome Research, Genome Biology and a prize-winning paper in GigaScience. In the past three years, he has contributed to the development of x8 open-source software, x2 web applications, and x4 databases for analysis of single-cell data and spatial transcriptomics. He is looking for enthusiastic research students and research staff to join his group.

Dr. Nguyen is an expert in applying long-read Oxford Nanopore Sequencing Technologies (ONT) in agriculture, particularly livestock and other sectors. Her groundbreaking contributions include being the pioneer in sequencing the genomes of Brahman and Wagyu cattle, developing an innovative epigenetic clock for age prediction in cattle, and successfully implementing ONT portable sequencers for Blockchain traceability systems in Australia.

As a leader in the field, Dr. Nguyen spearheads the use of ONT long-read technology to scaffold genome assemblies in livestock, plants, protists, and insects. Her multidisciplinary expertise in molecular biology, advanced genomics, and animal sciences also empowers her to explore causative markers for commercial SNP arrays and identify significant DNA variants from low-coverage sequencing data sets.

Dr. Nguyen's exceptional achievements and expertise have been acknowledged through the prestigious ARC Industry Fellowship, recognising her as a promising early career researcher. Her work has significantly contributed to advancing genomic research in agriculture and has opened new avenues for utilising ONT sequencing technologies across diverse domains.

Dr Cassandra Pattinson research centres around exploring the effects of sleep and circadian rhythms on health, wellbeing, and recovery across the lifespan. Dr Pattinson is a Senior Research Fellow at the Child Health Research Centre (CHRC) and the ARC centre of Excellence for the Digital Child. The Digital Child aims to support children growing up in the rapidly changing digital world, and provide strong evidence and guidance for children, families, educators, government and other concerned with children’s wellbeing. Her work has been supported by the ARC (including recently awarded an ARC Discovery Early Career Award, 2025), NHMRC, NIH and the DSTG, as well as the Australian Federal Government and Queensland Government.

Her research has involved a range of populations from children and adolescents, through to military personnel and athletes. Dr Pattinson's research spans a range of study designs and methodologies, including longitudinal studies tracking large child cohorts (>2000 children), standard observation techniques, survey and individualised standard child assessment, as well as studies employing physiological (actigraphy, spectrometry) and biological (hormones, proteomic, genomic) designs. Dr Pattinson also has a strong track record in research translation, these have included manuscripts in top scientific journals, reports for government and non-government organisations, development of professional development programs, as well as designing and presenting vodcasts and resources (e.g. fact sheets, workshops) to parent groups, young adults, government departments and the early childhood sector.

At CHRC Dr Pattinson is a part of the Community Sleep Health Group. This group collaborates with many other groups around broader issues of sleep and technology, sleep and the environment (including disasters), mental health and wellbeing, pain, disability, and new technologies and approaches.

My group's research uses large-scale genomic data to address knowledge gaps in disease, with a particular focus on cardiovascular disease.

Research programme

1. Cardiovascular disease research using big-data and genomics: with the goal of improving prevention and treatment of cardiovascular disease. By focusing on underrepresented groups, including women, my research aims to also address inequity in cardiovascular outcomes. I am the lead of the South Asian Genes and Health in Australia (SAGHA) study, which aims to increase representation of Australian South Asians in cardiovascular and genomics research. See saghaus.org for further details.

2. Drug genomics: I'm interested in using genomic approaches to predict drug effects, including identification of drug repurposing opportunities as well as identifying unknown adverse effects of medication.

3. Liver transplant research: In this collaboration with the QLD Liver Transplant Unit, we are using genomics to understand the effect of normo-thermic perfusion (a new organ storage method) on liver function, with the long-term goal of improving our ability to predict transplant outcomes.

Career summary: I was awarded my PhD from University College London (UK) in cardiovascular genetics. I began my post-doctoral fellowship under the mentorship of Prof Peter Visscher at the Queensland Brain Institute in 2013. Between 2016-2018, I was the lead analyst for the International Heart Failure Genetics Consortium (HERMES). In 2018, I was awarded an NHMRC Early Career Researcher Fellowship to investigate the relationship between cardiovascular and brain-related disorders using large-scale genetic and genomic data, under the mentorship of Prof Naomi Wray. I currently hold a National Heart Foundation Future Leader Fellowship.

Recognition:

2024 Australian Academy of Science Ruth Stephens Gani Medal for outstanding contribution to genetics research

2023 1 of 5 global finalists for the Nature Inspiring Women in Science (Scientific Achievement Award)

2023 Lifesciences QLD Rose-Anne Kelso Award

2023: Named in Australia's Top 25 Women in Science by Newscorp

2022 Queensland Young Tall Poppy Award

2022 UQ Foundation Research Excellence Award

2021/2022 Australian Superstar of STEM,

2020 Genetic Society of Australasia Early Career Award

2020 Women in Technology Rising Star Science Award

Critical Care Medicine focuses on supporting patients, often with one or multiple organ failures. Based at the largest Australian cardiac hospital, our research investigates better ways to support patients with heart and/or lung failure. We explore technological, pharmacological and engineering advances that could help our patients to live longer and better. Our group is world-renowned for clinically relevant large animal models, including heart failure, respiratory failure (ARDS), heart transplantation, sepsis, cardiogenic shock, and more. All our studies use hospital-grade equipment and follow the same clinical guideline to maximise translation. We actively take on honours, MPhil and PhD students from multi-disciplinary backgrounds (science, engineering, medicine, allied health), with a successful track record in supporting our students to secure their own grants and funding. Students are expected to contribute to other studies of the group. For more information about the group, please visit ccrg.org.au, and email if you are interested to join us.